Our current project focuses on the discovery of kinase inhibitors for the treatment of two critical conditions: Non-Small Cell Lung Cancer (NSCLC) and Chronic Lymphocytic Leukemia (CLL). Kinase inhibitors are promising therapeutic agents that target specific enzymes involved in cell growth and proliferation pathways, which are often dysregulated in cancer.

Our current project is focused on discovering inhibitors tailored for the treatment of Acute Myocardial Infarction (AMI), commonly referred to as a heart attack. By targeting specific enzymes and pathways involved in the progression of AMI, we aim to develop potent inhibitors capable of mitigating myocardial damage and reducing infarct size.

Our current project focuses on the discovery of novel inhibitors aimed at combating the processes associated with aging. By targeting specific molecular pathways involved in cellular senescence, DNA damage, inflammation, and oxidative stress, we aim to develop potent inhibitors capable of slowing down or reversing age-related changes at the cellular and organismal levels. Through rigorous screening, computational modeling, and preclinical studies, our goal is to identify lead compounds with the potential to extend healthspan, delay age-related diseases, and promote overall well-being in aging populations.